Anti-Human CD19 (Clone HD37) – Purified

Home/Primary Monoclonal Antibodies/SurfaceTag Human CD Markers/Anti-Human CD19 (Clone HD37) – Purified

Pricing & Details

Product No.C572
Clone
HD37
Protein
CD19
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Pan B-Cells, B-lymphocyte Surface Antigen B4
Isotype
Mouse
IgG1
Applications
FC
,
IP
Prod No.
Size
Price
Avail.
Qty
Add to cart
C572-0.1 mg
0.1 mg
$240.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Mouse
Product Concentration
0.1 mg/ml
Formulation
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Storage and Handling
For use within 1 month of purchase store at 2-8°C. For long term storage freeze working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone HD37 recognizes human CD19.
Antigen Distribution
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Background
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.

Antigen Details

Protein
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
PubMed
NCBI Gene Bank ID

References & Citations

1. Leukocyte Typing V (1995) Oxford University Press 2. Leukocyte Typing IV (1989) Oxford University Press 3. Leukocyte Typing III (1987) Oxford University Press 4. Leukocyte Typing II Oxford University Press
Flow Cytometry
Immunoprecipitation Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok